Supplementary Quarterly Financial Data (Unaudited)

12 Months Ended

Jun. 30, 2020

Supplementary Quarterly Financial Data (Unaudited)

19.	SUPPLEMENTARY QUARTERLY FINANCIAL DATA (UNAUDITED)

In millions, except per share amounts	Quarters Ended
	Jun 30,			Mar 31,			Dec 31,			Sep 30,
Consolidated Statement of Operations Data:	2020			2020			2019 (a)			2019
Molecular diagnostic testing	$	83.3		$	150.5		$	181.1		$	172.0
Pharmaceutical and clinical services		9.9			13.5			14.0			14.3
Total revenue		93.2			164.0			195.1			186.3
Costs and expenses:
Cost of molecular diagnostic testing		32.2			43.1			41.0			41.2
Cost of pharmaceutical and clinical services		4.5			7.0			8.6			8.5
Research and development expense		17.4			19.7			18.8			21.3
Change in the fair value of contingent consideration		—			(3.4	)		(0.1	)		0.7
Selling, general and administrative expense		107.4			132.9			134.3			135.5
Goodwill and intangible asset impairment charges		—			98.4			1.3			—
Total costs and expenses		161.5			297.7			203.9			207.2
Operating loss		(68.3	)		(133.7	)		(8.8	)		(20.9	)
Other income (expense):
Interest income		0.5			0.8			0.8			0.9
Interest expense		(3.1	)		(2.3	)		(2.5	)		(2.9	)
Other		12.4			4.1			(0.9	)		0.6
Total other income (expense)		9.8			2.6			(2.6	)		(1.4	)
Loss before income taxes		(58.5	)		(131.1	)		(11.4	)		(22.3	)
Income tax benefit		(3.0	)		(15.9	)		(3.1	)		(1.7	)
Net loss		(55.5	)		(115.2	)		(8.3	)		(20.6	)
Net loss attributable to non-controlling interest		(0.1	)		—			—			—
Net loss attributable to Myriad Genetics, Inc. stockholders	$	(55.4	)	$	(115.2	)	$	(8.3	)	$	(20.6	)
Loss per share:
Basic	$	(0.74	)	$	(1.55	)	$	(0.11	)	$	(0.28	)
Diluted	$	(0.74	)	$	(1.55	)	$	(0.11	)	$	(0.28	)
Weighted average shares outstanding:
Basic		74.6			74.5			74.4			73.7
Diluted		74.6			74.5			74.4			73.7

(a) An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

In millions, except per share amounts	Quarters Ended
	Jun 30,			Mar 31,			Dec 31,			Sep 30,
Consolidated Statement of Operations Data:	2019			2019			2018			2018
Molecular diagnostic testing	$	196.9		$	200.5		$	203.0		$	189.0
Pharmaceutical and clinical services		18.5			16.1			13.8			13.3
Total revenue		215.4			216.6			216.8			202.3
Costs and expenses:
Cost of molecular diagnostic testing		41.6			40.3			44.0			42.3
Cost of pharmaceutical and clinical services		9.0			8.3			8.1			7.4
Research and development expense		20.9			21.5			22.4			21.1
Change in contingent consideration		(0.3	)		—			1.0			0.4
Selling, general and administrative expense		149.8			140.6			135.2			129.9
Total costs and expenses		221.0			210.7			210.7			201.1
Operating income (loss)		(5.6	)		5.9			6.1			1.2
Other income (expense):
Interest income		0.9			0.7			0.9			0.7
Interest expense		(3.2	)		(3.2	)		(3.4	)		(2.2	)
Other		0.2			(0.1	)		—			1.1
Total other income (expense)		(2.1	)		(2.6	)		(2.5	)		(0.4	)
Income (loss) before income taxes		(7.7	)		3.3			3.6			0.8
Income tax provision (benefit)		(3.4	)		(3.6	)		1.0			1.6
Net income (loss)		(4.3	)		6.9			2.6			(0.8	)
Net loss attributable to non-controlling interest		(0.1	)		—			—			(0.1	)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$	(4.2	)	$	6.9		$	2.6		$	(0.7	)
Earnings (loss) per share:
Basic	$	(0.06	)	$	0.09		$	0.04		$	(0.01	)
Diluted	$	(0.06	)	$	0.09		$	0.03		$	(0.01	)
Weighted average shares outstanding:
Basic		73.4			73.3			74.2			73.0
Diluted		74.8			74.9			76.5			73.0